Trial Profile
A Multicenter Randomized Double-blind Active-controlled Parallel Group Phase III Trial to Evaluate the Equivalence in Efficacy and Safety of HD203 and Enbrel in Combination With Methotrexate in Patients With Rheumatoid Arthritis.
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 18 Oct 2021
Price :
$35
*
At a glance
- Drugs Etanercept (Primary) ; Methotrexate
- Indications Rheumatoid arthritis
- Focus Registrational; Therapeutic Use
- Acronyms HERA
- Sponsors Hanwha Chemical
- 08 Oct 2021 Results of meta-analysis of 3 randomized controlled trials (NCT01270997; NCT01895309 & NCT02357069) assessing efficacy and safety of etanercept biosimilars vs. etanercept originators in patients with active rheumatoid arthritis despite treatment with methotrexate, published in the International Journal of Clinical Pharmacology and Therapeutics.
- 23 Feb 2016 Results published in the Annals of the Rheumatic Diseases
- 14 Jul 2014 Status changed from recruiting to completed as reported by ClinicalTrials.gov record.